The company will focus on advancing a program in hematological malignancies and plans to launch a registrational trial in 2026.

The firm is now offering combined ex vivo drug sensitivity and genomic testing to cancer patients outside the clinical trial setting.

The firm is refocusing its resources on a KAT6A degrader for estrogen receptor-positive breast cancer and a previously undisclosed JAK2 Inhibitor.

The firm's stock tumbled on the news, dropping from $24.45 per share at market close Monday to $15.24 per share when the market opened Tuesday.

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...